Download PDF

1. Company Snapshot

1.a. Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.Janux Therapeutics, Inc.


is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies.The company was incorporated in 2017 and is headquartered in La Jolla, California.

Show Full description

1.b. Last Insights on JANX

Janux Therapeutics' recent performance was negatively impacted by a lack of recent earnings updates, with the last reported earnings release being in Q4 2024. However, the company's pipeline advancements, particularly its lead program JANX007, have shown promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. Despite this, insider buying activity has been minimal, with no notable purchases in recent weeks. The company's strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Dec -04

Source: fool.com

Card image cap

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Dec -02

Source: benzinga.com

Card image cap

Janux dives as gaps in prostate cancer study data worry investors

Dec -02

Source: reuters.com

Card image cap

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Dec -02

Source: barrons.com

Card image cap

Ensign Peak Advisors Inc Decreases Holdings in Janux Therapeutics, Inc. $JANX

Dec -02

Source: defenseworld.net

Card image cap

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Dec -02

Source: seekingalpha.com

Card image cap

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Dec -01

Source: businesswire.com

Card image cap

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Nov -18

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Novel Immunotherapies

Expected Growth: 11.3%

Janux Therapeutics' novel immunotherapies drive 11.3% growth, fueled by increasing adoption in cancer treatment, advancements in T-cell and bispecific antibody technologies, and a growing pipeline of promising candidates. Strong partnerships, strategic collaborations, and a robust research and development focus also contribute to the company's rapid expansion.

7. Detailed Products

T cell engagers

Janux Therapeutics' T cell engagers are bispecific antibodies designed to redirect T cells to tumor cells, enhancing the immune system's ability to fight cancer.

CD28-based costimulatory antibodies

Janux Therapeutics' CD28-based costimulatory antibodies are designed to enhance T cell activation and proliferation, promoting an anti-tumor immune response.

Tumor-targeted immunomodulators

Janux Therapeutics' tumor-targeted immunomodulators are designed to selectively modulate the tumor microenvironment, enhancing anti-tumor immunity and reducing immune suppression.

8. Janux Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Janux Therapeutics, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing novel and innovative therapies.

Bargaining Power Of Customers

Janux Therapeutics, Inc. has a diverse customer base, and no single customer has significant bargaining power over the company.

Bargaining Power Of Suppliers

Janux Therapeutics, Inc. relies on a few key suppliers for raw materials and services, but the company has developed relationships with multiple suppliers to mitigate the bargaining power of any one supplier.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services, posing a significant threat to Janux Therapeutics, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Janux Therapeutics, Inc. faces intense rivalry from established companies and new entrants, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 6.65%
Debt Cost 3.95%
Equity Weight 93.35%
Equity Cost 23.30%
WACC 22.02%
Leverage 7.13%

11. Quality Control: Janux Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Ionis Pharmaceuticals

A-Score: 4.2/10

Value: 6.0

Growth: 1.1

Quality: 4.5

Yield: 0.0

Momentum: 10.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Janux Therapeutics

A-Score: 3.8/10

Value: 9.0

Growth: 3.4

Quality: 7.9

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Revolution Medicines

A-Score: 3.7/10

Value: 6.4

Growth: 1.8

Quality: 6.4

Yield: 0.0

Momentum: 4.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 4.4

Growth: 7.6

Quality: 3.8

Yield: 0.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.8

Growth: 3.7

Quality: 6.2

Yield: 0.0

Momentum: 0.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Iovance Bio

A-Score: 3.1/10

Value: 8.2

Growth: 5.7

Quality: 3.9

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

16.51$

Current Price

16.51$

Potential

-0.00%

Expected Cash-Flows